Physician profile
Jacques Smith
NPI 1699170340
$2,647.64
in general payments reported to CMS, 2019-2025
20 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $436 · 2023: $381 · 2024: $1,003 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $900 · Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $900.00 |
| Food and Beverage | $870.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,125.00 | 2022-2024 | Symplicity G3 |
| Janssen Pharmaceuticals, INC | $468.79 | 2021-2024 | Xarelto |
| Angiodynamics, INC. | $240.49 | 2022-2025 | Venacure 1470 Pro |
| Novartis Pharmaceuticals Corporation | $198.83 | 2021-2023 | |
| Abiomed | $127.91 | 2025 | |
| Abbott Laboratories | $97.14 | 2024-2025 | Cardiomems, Navitor |
| Alnylam Pharmaceuticals INC. | $94.55 | 2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $52.88 | 2023-2024 | |
| Irhythm Technologies, INC. | $36.18 | 2024 | Zio Monitor, Zio Xt Patch |
| Bridgebio Pharma, INC. | $34.13 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $32.39 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $21.22 | 2025 | Evkeeza |
| Atricure, INC. | $18.17 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Cardiva Medical, INC. | $17.48 | 2025 | Cardiva Vascade 6/7f Vcs |
| Pfizer INC. | $16.15 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $15.81 | 2024 | |
| Esperion Therapeutics, INC. | $14.61 | 2023 | Nexletol |
| Merck Sharp & Dohme LLC | $12.82 | 2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $11.80 | 2021 | |
| Amgen INC. | $11.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacques Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.